CAR T-cell therapies have achieved unparalleled success in the treatment of relapsed and refractory blood cancers. Typically, CAR T-cell manufacture relies on the collection and modification of white blood cells taken from the patient they are to treat. This means that the composition and quality of starting material can vary, increasing the likelihood of manufacturing process failure. To help manufactures anticipate processing issues and adapt, this study explored the effect of specific cell populations on CAR T-cell production and product quality. Read the full article here:
AI Centre welcomes New Zealand’s Science Minister
The UCL Centre for Artificial Intelligence (AI Centre) was delighted to host a visit last week from Hon Dr Shane Reti, New Zealand's Minister of Science, Innovation and Technology.
11 Jul 2025
Bartlett students participate in Building a Better Future Consultancy project
The Building a Better Future (BABF) Consultancy Project has grown significantly since its pilot last year, now established as the Bartlett Faculty’s flagship Extended Learning Opportunities activity.
11 Jul 2025
Blog: Jal Sahelis: The women fighting drought in Bundelkhand
UCL Institute for Sustainable Resources student Rachel Buzinin details how women in drought-prone Bundelkhand, India, are transforming water management and challenging entrenched gender norms.
10 Jul 2025
